Cytomegalovirus antigen assay

Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. 49(RR10). Morbidity and Mortality Weekly Report. Alanta, Georgia, US. 2000. Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm. As accessed 7-26-05.

Salmon-Ceron D, Mazeron MC, Chaput S, et al: Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS 2000; 14:1041-1049.

Osarogiagbon RU, Defor TE, Weisdorf MA, et al: CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biology of Blood and Marrow Transplantation 2000; 6:280-288.

Chiaramonte S, Pellizzer G, Rassu M, et al: Role of antigenemia assay in the early diagnosis and treatment of CMV infection in renal transplant patients. Clinical Nephrology 2000; 53(4):10-12.

Boeckh M, Gallez-Hawkins GM, Myerson D, et al: Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplant 1997; 64(1):108- 113.

Bonin P, Tanino T, Handsfield H, et al: Isolation of Neisseria gonorrhoeae on selective and nonselective media in a sexually transmitted disease clinic. J Clin Microbiol 1984; 19:218-220.

Rawlinson WD: Broadsheet. Number 50: Diagnosis of human cytomegalovirus infection and disease. Pathology 1999; 31(2):109-115.